These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 32822291)

  • 1. Imaging Features of Vessels and Leakage Patterns Predict Extended Interval Aflibercept Dosing Using Ultra-Widefield Angiography in Retinal Vascular Disease: Findings From the PERMEATE Study.
    Moosavi A; Figueiredo N; Prasanna P; Srivastava SK; Sharma S; Madabhushi A; Ehlers JP
    IEEE Trans Biomed Eng; 2021 Jun; 68(6):1777-1786. PubMed ID: 32822291
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Radiomics-based assessment of ultra-widefield leakage patterns and vessel network architecture in the PERMEATE study: insights into treatment durability.
    Prasanna P; Bobba V; Figueiredo N; Sevgi DD; Lu C; Braman N; Alilou M; Sharma S; Srivastava SK; Madabhushi A; Ehlers JP
    Br J Ophthalmol; 2021 Aug; 105(8):1155-1160. PubMed ID: 32816791
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multi-Compartment Spatially-Derived Radiomics From Optical Coherence Tomography Predict Anti-VEGF Treatment Durability in Macular Edema Secondary to Retinal Vascular Disease: Preliminary Findings.
    Sil Kar S; Sevgi DD; Dong V; Srivastava SK; Madabhushi A; Ehlers JP
    IEEE J Transl Eng Health Med; 2021; 9():1000113. PubMed ID: 34350068
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Longitudinal Panretinal Leakage and Ischemic Indices in Retinal Vascular Disease after Aflibercept Therapy: The PERMEATE Study.
    Figueiredo N; Srivastava SK; Singh RP; Babiuch A; Sharma S; Rachitskaya A; Talcott K; Reese J; Hu M; Ehlers JP
    Ophthalmol Retina; 2020 Feb; 4(2):154-163. PubMed ID: 31757691
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Computational Imaging Biomarker Correlation with Intraocular Cytokine Expression in Diabetic Macular Edema: Radiomics Insights from the IMAGINE Study.
    Kar SS; Abraham J; Wykoff CC; Sevgi DD; Lunasco L; Brown DM; Srivastava SK; Madabhushi A; Ehlers JP
    Ophthalmol Sci; 2022 Jun; 2(2):100123. PubMed ID: 36249694
    [TBL] [Abstract][Full Text] [Related]  

  • 6. RETINAL LEAKAGE INDEX DYNAMICS ON ULTRA-WIDEFIELD FLUORESCEIN ANGIOGRAPHY IN EYES TREATED WITH INTRAVITREAL AFLIBERCEPT FOR PROLIFERATIVE DIABETIC RETINOPATHY IN THE RECOVERY STUDY.
    Babiuch AS; Wykoff CC; Srivastava SK; Talcott K; Zhou B; Hach J; Hu M; Reese JL; Ehlers JP
    Retina; 2020 Nov; 40(11):2175-2183. PubMed ID: 31917731
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Widefield OCT-Angiography and Fluorescein Angiography Assessments of Nonperfusion in Diabetic Retinopathy and Edema Treated with Anti-Vascular Endothelial Growth Factor.
    Couturier A; Rey PA; Erginay A; Lavia C; Bonnin S; Dupas B; Gaudric A; Tadayoni R
    Ophthalmology; 2019 Dec; 126(12):1685-1694. PubMed ID: 31383483
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association of Intravitreal Aflibercept With Optical Coherence Tomography Angiography Vessel Density in Patients With Proliferative Diabetic Retinopathy: A Secondary Analysis of a Randomized Clinical Trial.
    Alagorie AR; Nittala MG; Velaga S; Zhou B; Rusakevich AM; Wykoff CC; Sadda SR
    JAMA Ophthalmol; 2020 Aug; 138(8):851-857. PubMed ID: 32584384
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ultra-Widefield Fluorescein Angiography as a Biomarker for Response to Switch in Therapy in Persistent DME.
    Bahrami B; Hong T; Peto T; Chang A
    Ophthalmic Surg Lasers Imaging Retina; 2019 Dec; 50(12):771-778. PubMed ID: 31877222
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MEASUREMENTS OF RETINAL FLUID BY OPTICAL COHERENCE TOMOGRAPHY LEAKAGE IN DIABETIC MACULAR EDEMA: A Biomarker of Visual Acuity Response to Treatment.
    Santos AR; Alves D; Santos T; Figueira J; Silva R; Cunha-Vaz JG
    Retina; 2019 Jan; 39(1):52-60. PubMed ID: 29077605
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Retinal Microvasculature and Visual Acuity after Intravitreal Aflibercept in Diabetic Macular Edema: An Optical Coherence Tomography Angiography Study.
    Busch C; Wakabayashi T; Sato T; Fukushima Y; Hara C; Shiraki N; Winegarner A; Nishida K; Sakaguchi H; Nishida K
    Sci Rep; 2019 Feb; 9(1):1561. PubMed ID: 30733512
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Retinal Fluid Volatility Associated With Interval Tolerance and Visual Outcomes in Diabetic Macular Edema in the VISTA Phase III Trial.
    Ehlers JP; Uchida A; Sevgi DD; Hu M; Reed K; Berliner A; Vitti R; Chu K; Srivastava SK
    Am J Ophthalmol; 2021 Apr; 224():217-227. PubMed ID: 33253664
    [TBL] [Abstract][Full Text] [Related]  

  • 13. SEVERITY OF DIABETIC MACULAR EDEMA CORRELATES WITH RETINAL VASCULAR BED AREA ON ULTRA-WIDE FIELD FLUORESCEIN ANGIOGRAPHY: DAVE Study.
    Fan W; Uji A; Wang K; Falavarjani KG; Wykoff CC; Brown DM; Van Hemert J; Sagong M; Sadda SR; Ip M
    Retina; 2020 Jun; 40(6):1029-1037. PubMed ID: 31356494
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Persistent Macular Thickening Following Intravitreous Aflibercept, Bevacizumab, or Ranibizumab for Central-Involved Diabetic Macular Edema With Vision Impairment: A Secondary Analysis of a Randomized Clinical Trial.
    Bressler NM; Beaulieu WT; Glassman AR; Blinder KJ; Bressler SB; Jampol LM; Melia M; Wells JA;
    JAMA Ophthalmol; 2018 Mar; 136(3):257-269. PubMed ID: 29392288
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Optical Coherence Tomography Angiography in Diabetic Macular Edema Treated with Intravitreal Aflibercept: A 48-Week Observational Study (the DOCTA Study).
    Korobelnik JF; Gaucher D; Baillif S; Creuzot-Garcher C; Kodjikian L; Weber M
    Ophthalmologica; 2023; 246(2):71-80. PubMed ID: 36646050
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Optical coherence tomography angiography analysis of macular vessel density before and after anti-VEGF therapy in eyes with diabetic retinopathy.
    Sorour OA; Sabrosa AS; Yasin Alibhai A; Arya M; Ishibazawa A; Witkin AJ; Baumal CR; Duker JS; Waheed NK
    Int Ophthalmol; 2019 Oct; 39(10):2361-2371. PubMed ID: 31119505
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Foveal Microvascular Integrity Association With Anti-VEGF Treatment Response for Diabetic Macular Edema.
    Huang WH; Lai CC; Chuang LH; Huang JC; Wu CH; Lin YT; Yeung L
    Invest Ophthalmol Vis Sci; 2021 Jul; 62(9):41. PubMed ID: 34323921
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prospective study of aflibercept for the treatment of persistent macular oedema secondary to retinal vein occlusions in eyes not responsive to long-term treatment with bevacizumab or ranibizumab.
    Spooner K; Fraser-Bell S; Hong T; Chang A
    Clin Exp Ophthalmol; 2020 Jan; 48(1):53-60. PubMed ID: 31498950
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intravitreal ranibizumab versus aflibercept versus bevacizumab for macular oedema due to central retinal vein occlusion: the LEAVO non-inferiority three-arm RCT.
    Hykin P; Prevost AT; Sivaprasad S; Vasconcelos JC; Murphy C; Kelly J; Ramu J; Alshreef A; Flight L; Pennington R; Hounsome B; Lever E; Metry A; Poku E; Yang Y; Harding SP; Lotery A; Chakravarthy U; Brazier J
    Health Technol Assess; 2021 Jun; 25(38):1-196. PubMed ID: 34132192
    [TBL] [Abstract][Full Text] [Related]  

  • 20. NATURAL HISTORY AND PREDICTORS OF VISION LOSS IN EYES WITH DIABETIC MACULAR EDEMA AND GOOD INITIAL VISUAL ACUITY.
    Lent-Schochet D; Lo T; Luu KY; Tran S; Wilson MD; Moshiri A; Park SS; Yiu G
    Retina; 2021 Oct; 41(10):2132-2139. PubMed ID: 33734192
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.